|Dr. Alexandria Forbes||CEO, Pres & Director||10.27M||N/A||1965|
|Mr. Richard Brian Giroux||COO & CFO||9.58M||N/A||1973|
|Dr. Stuart Naylor Ph.D.||Chief Devel. Officer||1.14M||N/A||1963|
|Ms. Elizabeth Broder||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Micah Zajic||VP of Corp. Devel.||N/A||N/A||N/A|
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is headquartered in New York, New York.
MeiraGTx Holdings plc’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 7; Compensation: 8.